Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;375(13):1303. https://doi.org/10.1056/NEJMc1609622.
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84. https://doi.org/10.1016/S0140-6736(16)31591-4.
Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73.
Ma KS, Lee YH, Lin CJ, Shih PC, Wei JC. Management of extra-articular manifestations in spondyloarthritis. Int J Rheum Dis. 2023;26(2):183–6. https://doi.org/10.1111/1756-185X.14485.
Wendling D, Hecquet S, Fogel O, Letarouilly JG, Verhoeven F, Pham T, et al. 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. Joint Bone Spine. 2022;89(3): 105344. https://doi.org/10.1016/j.jbspin.2022.105344.
Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. https://doi.org/10.1136/ard-2022-223296.
Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3–17. https://doi.org/10.1136/annrheumdis-2017-211734.
McGonagle D, Ramonda R, Scagnellato L, Scriffignano S, Weddell J, Lubrano E. A strategy towards disentangling treatment refractory from misdiagnosed axial spondyloarthritis. Autoimmun Rev. 2024;23(1): 103405. https://doi.org/10.1016/j.autrev.2023.103405.
Benavent D, Franco-Gómez K, Plasencia-Rodriguez C, Novella-Navarro M, Bogas P, Nieto R, et al. Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain. BMJ Open. 2022;12(4): e057850. https://doi.org/10.1136/bmjopen-2021-057850.
Article PubMed PubMed Central Google Scholar
Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Diaz Del Campo P, Balsa A, Gratacós J. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open. 2017;3(2): e000524. https://doi.org/10.1136/rmdopen-2017-000524.
Article PubMed PubMed Central Google Scholar
Linde L, Ørnbjerg LM, Brahe CH, Wallman JK, Di Giuseppe D, Závada J, et al. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching. Rheumatology (Oxford). 2023. https://doi.org/10.1093/rheumatology/kead494.
Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–5. https://doi.org/10.1136/annrheumdis-2020-217344.
Fagni F, Motta F, Schett G, Selmi C. Difficult-to-treat psoriatic arthritis: a conceptual approach. Arthritis Rheumatol. 2024;76(5):670–4. https://doi.org/10.1002/art.42780.
Wendling D, Verhoeven F, Prati C. Is the Difficult-to-Treat (D2T) concept applicable to axial spondyloarthritis? Joint Bone Spine. 2023;90(3): 105512. https://doi.org/10.1016/j.jbspin.2022.105512.
Philippoteaux C, Delepine T, Cailliau E, Philippe P, Taisne N, Pascart T, et al. Characteristics of difficult-to-treat axial spondyloarthritis: results of a real-world multicentric study. Joint Bone Spine. 2024;91(2): 105670. https://doi.org/10.1016/j.jbspin.2023.105670.
Article CAS PubMed Google Scholar
Poddubnyy D, Baraliakos X, Navarro-Compán V, Torgutalp M, van der Heijde D, the ASAS Difficult-to-Manage Axial Spondyloarthritis Task Force. The assessment of spondyloarthritis international society (asas) definition of difficultto-manage axial spondyloarthritis. (Abstract O11). Clin Exp Rheumatol. 2024;42(9):12–3 (Fourteenth International Congress on Spondyloarthritides (clinexprheumatol.org) CER18127).
Di Giuseppe D, Lindström U, Aaltonen K, Relas H, Provan S, Gudbjornsson B, et al. The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2021. https://doi.org/10.1093/rheumatology/keab946.
Fakih O, Desmarets M, Martin B, Prati C, Monnet E, Verhoeven F, et al. Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study. RMD Open. 2023;9(4): e003461. https://doi.org/10.1136/rmdopen-2023-003461.
Article PubMed PubMed Central Google Scholar
Juárez M, Benavent D, Navarro-Compán V, NovellaNavarro M, Peiteado D, Villalba A, et al. The challenge of identifying difficult-totreat axial spondyloarthritis in clinical practice: results from La Paz-Spa cohort (POS0676). Ann Rheum Dis. 2023;82(Suppl1):619–20. https://doi.org/10.1136/annrheumdis-2023-eular.4910.
Montero F, Berbel Arcobé L , Carpio Astudillo K , Bellon JM, Juanola Roura X. Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes Abstract Number: 2224. Arthritis Rheum. 2023;75 Abstract supplement:4386-9
Wendling D, Breban M, Costantino F, Lequerré T, Felten R, Ruyssen-Witrand A, et al. Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop. Joint Bone Spine. 2024. https://doi.org/10.1016/j.jbspin.2024.105741.
Tsiami S, Baraliakos X. Pearls and pitfalls in diagnosing non-radiographic axial spondyloarthritis. Mediterr J Rheumatol. 2022;33(Suppl 1):109–14. https://doi.org/10.31138/mjr.33.1.109.
Article PubMed PubMed Central Google Scholar
Slobodin G, Lidar M, Eshed I. Clinical and imaging mimickers of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47(3):361–8. https://doi.org/10.1016/j.semarthrit.2017.05.009.
Mease P, Deodhar A. Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review. BMC Musculoskelet Disord. 2022;23(1):240. https://doi.org/10.1186/s12891-022-05073-7.
Article PubMed PubMed Central Google Scholar
Juanola X, Ramos MJM, Belzunegui JM, Fernández-Carballido C, Gratacós J. Treatment failure in axial spondyloarthritis: insights for a standardized definition. Adv Ther. 2022;39(4):1490–501. https://doi.org/10.1007/s12325-022-02064-x.
Article CAS PubMed PubMed Central Google Scholar
Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983–1028. https://doi.org/10.1007/s12325-015-0256-7.
Article PubMed PubMed Central Google Scholar
Goupille P, Vuitton L, Wendling D. Axial spondyloarthritis and inflammatory bowel disease: therapeutic implications. Joint Bone Spine. 2024;91(4): 105720. https://doi.org/10.1016/j.jbspin.2024.105720.
Bosch P, Zhao SS, Nikiphorou E. The association between comorbidities and disease activity in spondyloarthritis—a narrative review. Best Pract Res Clin Rheumatol. 2023;37(3): 101857. https://doi.org/10.1016/j.berh.2023.101857.
Avouac J, Fogel O, Hecquet S, Daien C, Elalamy I, Picard F, et al. Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases. Joint Bone Spine. 2023;90(5): 105592. https://doi.org/10.1016/j.jbspin.2023.105592.
Article CAS PubMed Google Scholar
Bixio R, Bonetto C, Fracassi E, Ristic B, Mastropaolo F, Pacenza G, et al. Depression as a possible determinant of fatigue in patients with axial spondyloarthritis. Clin Exp Rheumatol. 2024;42(5):1015–9. https://doi.org/10.55563/clinexprheumatol/d4cq48.
Kilic G, Kilic E, Ozgocmen S. Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis. Medicine (Baltimore). 2014;93(29): e337. https://doi.org/10.1097/MD.0000000000000337.
留言 (0)